Neuropsychiatric Side Effects of Montelukast
Between 16-32% of children taking montelukast develop neuropsychiatric side effects, with the most robust real-world evidence showing approximately 16% discontinue the medication due to these effects.
Key Evidence on Incidence
The FDA drug label states "no specific adverse effects have been identified" for montelukast 1, and the 2007 EPR-3 guidelines similarly note "no specific adverse effects" 2. However, these guideline statements are outdated and contradicted by substantial recent research evidence.
Real-World Incidence Data
The most clinically relevant study found that 16% (95% CI: 10-26%) of children discontinued montelukast specifically due to neuropsychiatric adverse drug reactions, with most occurring within 2 weeks of initiation 3. This represents a 12-fold higher risk compared to inhaled corticosteroids 3.
A prospective real-time study demonstrated even higher rates: 62.4% of children (78 out of 125) experienced neuropsychiatric ADRs when actively monitored 4. This suggests retrospective studies significantly underestimate the true incidence.
Large database studies show more modest but still significant increases:
- 32% increased risk of any neuropsychiatric outcome (71 per 1000 vs 54 per 1000; Number Needed to Harm = 58 patients) 5
- 34% increased risk over 14-day period (aOR 1.34,95% CI 1.31-1.37) 6
Specific Neuropsychiatric Effects
The most common manifestations include:
Sleep disturbances (most frequent):
- 63% increased risk 5
- Affects 15.1% of children 7
- Includes nightmares, sleep interruption, and decreased sleep quality
Behavioral changes:
Mood disorders:
- 16% increased risk of anxiety 5
- 11% increased risk of anxiety in meta-analysis 8
- 16% increased risk of mood disorders 5
Contradictory Evidence
One large Swedish study found NO association between montelukast and neuropsychiatric events (HR 0.99,95% CI 0.84-1.16) 9. However, this study compared montelukast to LABAs (which may also have neuropsychiatric effects), rather than placebo or no treatment, potentially masking the true risk.
Clinical Implications
The discrepancy between FDA labeling and real-world evidence is striking. While official sources claim no specific adverse effects, prospective monitoring reveals that nearly two-thirds of children experience some neuropsychiatric symptoms, with one in six discontinuing therapy.
Important Caveats
- Timing: Most reactions occur within the first 2 weeks of treatment 3
- Reversibility: All neuropsychiatric ADRs resolved upon drug discontinuation 7, 4
- Age vulnerability: Highest prevalence in children aged 4-9 years (52.8%) 7
- Quality of life impact: Children experiencing ADRs had significantly worse QoL scores across all domains 4
Practical Recommendations
Given this evidence, counsel all families about the 16-32% risk of neuropsychiatric effects before initiating montelukast, emphasizing sleep disturbances, behavioral changes, and mood symptoms. Schedule close follow-up within 2 weeks of initiation, and discontinue immediately if concerning symptoms emerge, as effects are fully reversible.